sglt2 inhibitors and glp-1 receptor agonists Agonist Therapy With Without in Patients With Type 2 Diabetes Mechanisms underlying favorable effects of

Another positive finding was seen in 60 patients with BED and T2DM when dulaglutide, which is not currently licensed for obesity, was compared with placebo at 12 weeks 222

Although past meta-analyses reported substantial reductions in MACE with DPP-4 inhibitors [23], their conclusions were based on studies with small sample sizes and limited numbers of cardiovascular events, which have not been confirmed by the four CVOTs specifically designed to assess the CV safety of DPP-4 inhibitors

It promotes the breakdown of fatty acids

While gastroparesis raises concerns, no confirmed increased aspiration risk has been established

Cardiovascular Risks While some GLP-1 drugs improve heart health, patients with existing heart conditions require close monitoring

Additionally, a laboratory study found evidence that GLP-1 drugs may slow the growth of lung cancer cells